Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • AYUSH
    • Commercialisation of...

    Commercialisation of Ayush Drugs, Technologies: New policy calls for 4 percent royalty to CCRAS

    GarimaWritten by Garima Published On 2019-01-16T17:20:28+05:30  |  Updated On 16 Jan 2019 5:20 PM IST
    Commercialisation of Ayush Drugs, Technologies: New policy calls for 4 percent royalty to CCRAS

    The policy focuses on the commercialisation of the various AYUSH drugs, Processes, Instrumentation that is developed by CCRAS. The various technologies are divided into three categories and will attract 4% Ex-factory Sales as royalty for the CCRAS


    New Delhi: The novel ayurvedic drugs would now be accessible at pharmacies at a quicker pace. The Union minister of state for Ayush, Shripad Naik has approved the proposed policy to accelerate the commercialization procedure of technologies. This policy comprises of different categories of the products/technologies and processes need to be transferred for further commercialization.


    The Central Council of Research in Ayurvedic Sciences (CCRAS), an autonomous body under Ministry of AYUSH, Govt. of India is an apex body in India for the undertaking, coordinating, formulating, developing and promoting research on scientific lines in Ayurvedic Sciences.


    The council has been developing and validating drugs and technologies process at in-house Research & Development facilities and also in collaboration with reputed organizations.


    Given the scenario, CCRAS prepared the guidelines that focused on transferring technology to industry, calculating royalty and resolving intellectual property rights issues. This policy has provisions for Benchmarks for undertaking research/research consultation for already commercialized/ marketed Ayurveda Products in the existing CCRAS Research Policy.

    Further, the Drugs, Technologies and process etc. developed by the Council are being commercialized through National Research Development Corporation (NRDC).


    In view of the expansion of the scope of R&D and its commercialization as per the provisions of CCRAS Research Policy, different categories of the products/technologies and processes need to be transferred for further commercialization.


    According to the CCRAS Commercialisation Policy document technologies are grouped into three different categories;




    • Category I includes independently developed technologies

    • Category II includes technologies developed with collaborative efforts

    • Category III includes the development of value-added technologies.


    The royalty is set at 4% of ex-factory sales and the rounded premium would be calculated on a case-to-case basis depending on commercial viability and translational value.


    Also Read: Immense scope for medical tourism between India, Netherlands: Ayush Minister

    AyushCCRAScommercial viabilitycommercialisation of technologiesdrugsgovt of indiaMinistry of AyushNational Research Development CorporationNRDCpolicy for commercialisationtraditional medicinestranslational value

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok